MiNK Therapeutics Inc (NAS:INKT)

Q3 2025 Mink Therapeutics Inc Earnings Call Transcript

Nov 14, 2025 / 01:30 PM GMT

Release Date Price: $12.75 (-3.56%)

Transcript 10-Q

Key Points

Positve

MiNK Therapeutics Inc (INKT) reported remarkable clinical trial results, with patients receiving their INKT cell therapy, agent 797, showing a median overall survival of approximately 23 months in a refractory setting.
The company observed complete remission in a patient with metastatic testicular cancer and durable partial response in a second-line gastric cancer patient, highlighting the potential of agent 797.
Agent 797 demonstrated durable activity across multiple difficult-to-treat cancers without the common toxicities associated with other cell therapies, such as cytokine release syndrome or neurotoxicity.
MiNK Therapeutics Inc (INKT) has established strategic partnerships, including collaborations with the University of Wisconsin and federal institutions, to advance their INKT program and secure funding through public-private grants.
The company has strengthened its leadership team and board, enhancing its strategic direction and execution capabilities, with notable additions like Dr. John Holcomb and Dr. Terese Hammond.

Negative

MiNK Therapeutics Inc (INKT) reported a net loss of $2.9 million for the third quarter of 2025, an increase from the previous year's loss of $1.8 million for the same period.
The company faces the challenge of expanding its clinical trials, particularly in the combination therapy cohort, which currently has a small sample size.
There is uncertainty regarding the timing of the launch for the severe pulmonary disease trial, with potential delays into early next year.
Despite promising results, the company is still in the early stages of clinical development, with many programs yet to reach pivotal trials.
The financial sustainability of MiNK Therapeutics Inc (INKT) relies heavily on securing additional funding and partnerships to support its ongoing and future clinical programs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INKT.OQ - Mink Therapeutics Inc
Q3 2025 Mink Therapeutics Inc Earnings Call
Nov 14, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Mink Therapeutic's 3rd quarter 2025 conference call and webcast. All participants will be in a listen-only mode until the question-and-answer session.

Please note this event is being recorded. If anyone has any objections, you may disconnect at this time.

I would now like to turn the conference over to Stephanie Pernanakar, Chief Communications Officer. Stephanie, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.